 |
 |
Gleanings From PDF Newsletter (Summer 1996) -Volunteers sought for trial of OPC14117 at Bethesda, MD -Volunteers sought for study of dextromethorphan, same site -Postmenopausal volunteers sought for study of effects of estrogen on PD symptoms and on response to levodopa. -Somerset Pharmaceuticals received FDA clearance to market Eldepryl in 5mg aquamarine capsule, instead of the familiar white tablet. Claimed easier to recognize and easier to swallow. Also, there is no approved "liquid Eldepryl". -10 more subjects still wanted for double-blind fetal tissue trial. PET scans will be done at Cornell, Surgery at U Colorado in Denver, and continued follow-up at Columbia-Presbyterian (New York City). -Entacapone is now in phase III (final) trials; will be marketed by Sandoz, who also market Sinemet, Eldepryl, and Parlodel. -Nebraska is setting up the nation*s first statutory PD registry. -Our "Parkinsn" list is mentioned but no contact given. -A new monthly newsletter, NeuroScience NEWS, will be published at $36/ year. For further detail on any item, consult the Parkinson*s Disease Foundation at 710 West 168 th Street, New York, NY 10032-9982. Cheers, Joe J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks CA 91403